N Mahaleh Yousefi - Pharma

Author Information

Nazila Yousefi is a distinguished researcher affiliated with the Department of Pharmacoeconomics and Pharma Management at the School of Pharmacy, Shahid Beheshti University of Medical Sciences in Tehran, Iran. Her work primarily focuses on the intersection of pharmaceutical management and economic policies, which is pivotal in shaping the healthcare landscape in Iran and beyond.

Research Contributions

Nazila Yousefi has made significant contributions to the field of pharmacoeconomics and pharmaceutical management. Her research covers a wide array of topics, including pharmaceutical advertising, drug utilization studies, and the economic aspects of the pharmaceutical industry. Notably, her work has explored the impact of intellectual property rights on the pharmaceutical sector in developing countries, as well as the determinants of pharmaceutical expenditure in Iran and selected OECD countries. She has also investigated the pricing of domestically produced medicines compared to similar generics in other countries, emphasizing the importance of innovation capability in new product performance.

Aliases

Throughout her academic career, Nazila Yousefi has been referenced by various aliases, including N Mahaleh Yousefi, N Yousefi, and N. Yousefi. These aliases reflect variations in her name as it appears in different publications and databases.

Publication and Citation Metrics

Metric	Value
Number of Papers	73
Citation Count	258
H-index	9

Publications:

An investigation into the pharmaceutical advertising in Iranian medical journals

DOI: 10.1186/s40545-022-00415-1

Year: 2022

A ten-year study of anti-diabetic drugs utilization in Iran

DOI: 10.1007/s40200-022-00983-8

Year: 2022

Comparison of Price regarding the Domesticly Produced Medicine with the Price of the Similar Generic Medicine in India

DOI: 10.18502/mshsj.v6i4.8989

Year: 2022

Intellectual resource and new product performance: mediating role of innovation capability

DOI: 10.1504/ijlic.2022.121254

Year: 2022

How Much Iranian Parents Know of and How Well They Practice Regarding Antibiotics?

DOI: 10.22037/ijpr.2020.113695.14433

Year: 2021

Evaluation of Iran's pharmaceutical policies in the import of drugs and determining the nature of imported drugs using the ABC-VED Method

DOI: 10.18502/mshsj.v6i2.7180

Year: 2021

Investigation the determinants of pharmaceutical expenditure share of GDP in Iran and selected OECD countries

DOI: 10.1186/s40545-021-00371-2

Year: 2021

Impact of the Trade-Related Aspect of Intellectual Property Rights Agreement on Pharmaceutical Industry in Developing Countries: A Scoping Review

DOI: 10.22037/ijpr.2021.115264.15282

Year: 2021

The Effect of Organizational Resilience and Strategic Foresight on Firm Performance: Competitive Advantage as Mediating Variable

DOI: 10.22037/ijpr.2021.116145.15723

Year: 2021

Intellectual resource and new product performance: mediating role of innovation capability

DOI: 10.1504/ijlic.2021.10040580

Year: 2021

How Does the Patent System Affect Generic Competition?

How Does Pharma Play a Role in Chronic Conditions?

What are the Key Challenges?

What Are the Challenges of Clinical Trials?

What is Geriatric Care in Pharma?

What is a New Drug Application (NDA)?

What are the Challenges in Implementing Collaborative Care Models?

How Can Pharma Companies Improve Patient Education?

What are Collaborative Care Models?

Who Can Participate in Clinical Trials?

Partnered Content Networks

Relevant Topics